Ptc Therapeutics share price today

(PTCT)

Ptc Therapeutics share price is $46.24 & ₹3,929.29 as on 21 Dec 2024, 2.30 'hrs' IST

$46.24

▲

0.99

(2.19%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Ptc Therapeutics share price in Dollar and Rupees. Guide to invest in Ptc Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Ptc Therapeutics. Get details on the Indian mutual funds that are investing in Ptc Therapeutics. Get Analyst recommendations and forecasts along with all the Ptc Therapeutics's financials.

Ptc Therapeutics share price movements

Today's Low: $44.76
Today's High: $47.42
$46.24
3.2%
Downside
Day's Volatility :5.61%
Upside
2.49%
52 Weeks Low: $23.58
52 Weeks High: $54.16
$46.24
49.01%
Downside
52 Weeks Volatility :56.46%
Upside
14.62%

Ptc Therapeutics Returns

Period	Ptc Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	25.82%	-11.1%	0.0%
6 Months	29.27%	-6.0%	0.0%
1 Year	67.48%	2.7%	0.0%
3 Years	13.19%	0.6%	-19.7%

Ptc Therapeutics Key Statistics

in dollars & INR

Previous Close	$45.25
Open	$44.77
Today's High	$47.42
Today's Low	$44.76
Market Capitalization	$3.6B
Today's Volume	$1.2M
52 Week High	$54.16
52 Week Low	$23.58
Revenue TTM	$900.7M
EBITDA	$21.8M
Earnings Per Share (EPS)	$-5.94
Profit Margin	-50.32%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-7740.12%

How to invest in Ptc Therapeutics from India?

It is very easy for Indian residents to invest directly in Ptc Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ptc Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Ptc Therapeutics or PTCT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ptc Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ptc Therapeutics shares which would translate to 0.018 fractional shares of Ptc Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Ptc Therapeutics, in just a few clicks!

Returns in Ptc Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Ptc Therapeutics investment value today

Current value as on today

₹1,69,672

Returns

₹69,672

(+69.67%)

Returns from Ptc Therapeutics Stock

₹67,476 (+67.48%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Ptc Therapeutics

62%

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Ptc Therapeutics on INDmoney from India has grown in the last 30 days as on Dec 21, 2024. 62% more investors are searching Ptc Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Ptc Therapeutics

Vanguard Group Inc
11.83%
Wellington Management Company LLP
10.23%
BlackRock Inc
10.08%
RTW INVESTMENTS, LLC
9.59%
Armistice Capital, LLC
9.38%
COWEN AND COMPANY, LLC
4.66%

Analyst Recommendation on Ptc Therapeutics

Buy

50%Buy

30%Hold

20%Sell

Based on 20 Wall street analysts offering stock ratings for Ptc Therapeutics(by analysts ranked 0 to 5 stars)

Based on 20 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Ptc Therapeutics

What analysts predicted

Upside of 26.98%

Current:

$46.24

Target:

$58.71

Insights on Ptc Therapeutics

Price Movement
In the last 1 year, PTCT stock has moved up by 62.7%
Increasing Revenue
Revenue is up for the last 2 quarters, 186.70M → 196.78M (in $), with an average increase of 5.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -91.57M → -106.65M (in $), with an average decrease of 7.9% per quarter
PTCT vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 7.7%

Ptc Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$264.7M	↑ 36.19%
Net Income	$-128.1M	↑ 62.13%
Net Profit Margin	-48.38%	↓ 7.74%

	FY19	Y/Y Change
Revenue	$307.0M	↑ 15.96%
Net Income	$-251.6M	↑ 96.42%
Net Profit Margin	-81.95%	↓ 33.57%

	FY20	Y/Y Change
Revenue	$380.8M	↑ 24.04%
Net Income	$-438.2M	↑ 74.17%
Net Profit Margin	-115.07%	↓ 33.12%

	FY21	Y/Y Change
Revenue	$538.6M	↑ 41.45%
Net Income	$-523.9M	↑ 19.57%
Net Profit Margin	-97.27%	↑ 17.8%

	FY22	Y/Y Change
Revenue	$698.8M	↑ 29.75%
Net Income	$-559.0M	↑ 6.7%
Net Profit Margin	-80.0%	↑ 17.27%

	FY23	Y/Y Change
Revenue	$937.8M	↑ 34.2%
Net Income	$-626.6M	↑ 12.09%
Net Profit Margin	-66.81%	↑ 13.19%

	Q2 FY23	Q/Q Change
Revenue	$213.8M	↓ 2.98%
Net Income	$-198.9M	↑ 43.12%
Net Profit Margin	-93.02%	↓ 29.97%

	Q3 FY23	Q/Q Change
Revenue	$196.6M	↓ 8.06%
Net Income	$-133.0M	↓ 33.14%
Net Profit Margin	-67.64%	↑ 25.38%

	Q4 FY23	Q/Q Change
Revenue	$307.1M	↑ 56.2%
Net Income	$-155.8M	↑ 17.16%
Net Profit Margin	-50.74%	↑ 16.9%

	Q1 FY24	Q/Q Change
Revenue	$210.1M	↓ 31.57%
Net Income	$-91.6M	↓ 41.22%
Net Profit Margin	-43.58%	↑ 7.16%

	Q2 FY24	Q/Q Change
Revenue	$186.7M	↓ 11.14%
Net Income	$-99.2M	↑ 8.3%
Net Profit Margin	-53.12%	↓ 9.54%

	Q3 FY24	Q/Q Change
Revenue	$196.8M	↑ 5.4%
Net Income	$-106.7M	↑ 7.54%
Net Profit Margin	-54.2%	↓ 1.08%

	FY18	Y/Y Change
Profit	$252.1M	↑ 32.79%

	FY19	Y/Y Change
Profit	$294.8M	↑ 16.97%

	FY20	Y/Y Change
Profit	$361.8M	↑ 22.72%

	FY21	Y/Y Change
Profit	$506.3M	↑ 39.92%

	FY22	Y/Y Change
Profit	$654.1M	↑ 29.21%

	FY23	Y/Y Change
Profit	$872.3M	↑ 33.36%

	Q2 FY23	Q/Q Change
Profit	$201.1M	↓ 2.5%

	Q3 FY23	Q/Q Change
Profit	$187.1M	↓ 6.96%

	Q4 FY23	Q/Q Change
Profit	$200.8M	↑ 7.31%

	Q1 FY24	Q/Q Change
Profit	$143.8M	↓ 28.35%

	Q2 FY24	Q/Q Change
Profit	$168.3M	↑ 17.01%

	Q3 FY24	Q/Q Change
Profit	$185.9M	↑ 10.47%

	FY18	Y/Y Change
Operating Cash Flow	$-27.6M	↑ 174.68%
Investing Cash Flow	$-42.6M	↓ 424.87%
Financing Cash Flow	$131.6M	↑ 197.55%

	FY19	Y/Y Change
Operating Cash Flow	$-98.6M	↑ 256.86%
Investing Cash Flow	$-387.2M	↑ 808.73%
Financing Cash Flow	$613.2M	↑ 366.07%

	FY20	Y/Y Change
Operating Cash Flow	$-194.1M	↑ 96.75%
Investing Cash Flow	$-561.5M	↑ 45.01%
Financing Cash Flow	$668.7M	↑ 9.05%

	FY21	Y/Y Change
Operating Cash Flow	$-251.3M	↑ 29.51%
Investing Cash Flow	$219.2M	↓ 139.03%
Financing Cash Flow	$20.9M	↓ 96.88%

	FY22	Y/Y Change
Operating Cash Flow	$-356.7M	↑ 41.91%
Investing Cash Flow	$290.2M	↑ 32.39%
Financing Cash Flow	$168.0M	↑ 704.48%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-14.1M	↓ 52.12%
Investing Cash Flow	$-23.8M	↓ 18.01%
Financing Cash Flow	$18.5M	↑ 350.9%

Ptc Therapeutics Technicals Summary

Sell

Neutral

Buy

Ptc Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Ptc Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ptc Therapeutics, Inc.	7.81%	29.27%	67.48%	13.19%	-6.26%
Regeneron Pharmaceuticals, Inc.	-5.73%	-34.03%	-17.11%	13.66%	87.56%
Biontech Se	4.48%	30.56%	7.36%	-56.46%	225.6%
Alnylam Pharmaceuticals, Inc.	-0.55%	10.11%	28.49%	30.99%	109.19%
Vertex Pharmaceuticals Incorporated	-11.79%	-16.36%	-1.97%	78.33%	80.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ptc Therapeutics, Inc.	NA	NA	0.81	-4.26	-77.4	-0.05	NA	-13.7
Regeneron Pharmaceuticals, Inc.	17.51	17.51	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.55	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ptc Therapeutics, Inc.	Buy	$3.6B	-6.26%	NA	-50.32%
Regeneron Pharmaceuticals, Inc.	Buy	$77.8B	87.56%	17.51	33.61%
Biontech Se	Buy	$26.7B	225.6%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.8B	109.19%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$102.1B	80.59%	32.84	-4.51%

Ptc Therapeutics Dividend announcements

Ptc Therapeutics Earnings
Ptc Therapeutics’s price-to-earnings ratio stands at None
Read More

About Ptc Therapeutics

ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.

Organization	Ptc Therapeutics
Employees	988
CEO	Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Industry	Health Technology

Management People of Ptc Therapeutics

Name	Title
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.	CEO & Director
Dr. Stuart W. Peltz Ph.D.	Co-Founder, Senior Consultant & Member of Scientific Advisory Board
Dr. Allan Steven Jacobson Ph.D.	Co-Founder, Chairman of Scientific Advisory Board & Independent Director
Mr. Pierre Gravier M.S.	Chief Financial Officer
Mr. Mark Elliott Boulding J.D.	Executive VP & Chief Legal Officer
Mr. Eric Pauwels	Chief Business Officer
Dr. Lee Golden M.D., Ph.D.	Executive VP & Chief Medical Officer
Ms. Christine Utter CPA	Senior VP, Chief Accounting Officer & Head of People Services
Dr. Neil Almstead Ph.D.	Chief Technical Operations Officer
Ms. Linda Montella Carter	Senior VP & Chief Information Officer

Important FAQs about investing in Ptc Therapeutics from India :

What is Ptc Therapeutics share price today?

Ptc Therapeutics share price today stands at $46.24, Open: $44.77 ; Previous Close: $45.25 ; High: $47.42 ; Low: $44.76 ; 52 Week High: $54.16 ; 52 Week Low: $23.58. The stock opens at $44.77, after a previous close of $45.25. The stock reached a daily high of $47.42 and a low of $44.76, with a 52-week high of $54.16 and a 52-week low of $23.58.

Can Indians buy Ptc Therapeutics shares?

Yes, Indians can invest in the Ptc Therapeutics (PTCT) from India.

With INDmoney, you can buy Ptc Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Ptc Therapeutics at zero transaction cost.

How can I buy Ptc Therapeutics shares from India?

It is very easy to buy Ptc Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ptc Therapeutics be purchased?

Yes, you can buy fractional shares of Ptc Therapeutics with INDmoney app.

What are the documents required to start investing in Ptc Therapeutics stocks?

To start investing in Ptc Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.